Top Markets
Coin of the day
PHAXIAM Therapeutics S.A. PHAXIAM Therapeutics S.A.

PHAXIAM Therapeutics S.A.

PHXM
주식 순위 #39465
PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating... PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating therapies for drug-resistant bacterial infections, operating in both France and the U.S. The company's pipeline includes eryaspase, currently undergoing Phase 3 clinical trials for advanced pancreatic cancer and Phase 2 studies for treating triple-negative breast cancer and acute lymphoblastic leukemia after initial treatments. Additionally, PHAXIAM is advancing a range of phage therapies designed to combat hazardous, drug-resistant bacteria. These pathogens, such as Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, are responsible for over two-thirds of all resistant infections acquired in hospital settings. Established in 2004, the company was previously known as ERYTECH Pharma S.A. before adopting the name PHAXIAM Therapeutics S.A. in June 2023. Its corporate headquarters are located in Lyon, France.
주가
$0.11725176
마지막 동기화: 2025-07-14
시가총액
$481.50K
변동 (1일)
-0.20%
변동 (1년)
0.00%
국가
FR
거래 PHAXIAM Therapeutics S.A. (PHXM)

카테고리

PHAXIAM Therapeutics S.A. (PHXM)의 매출
Jun 2024 기준 매출 TTM: $2.30M
PHAXIAM Therapeutics S.A.의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 $2.30M입니다. 2022년에 회사는 $7.13M의 수익을 올렸으며 이는 2021년의 $4.75M 대비 증가입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
PHAXIAM Therapeutics S.A.의 수익 기록 (2016 ~ 2026)
매년 말 매출
연도 매출 변화
2026 (TTM) $2.30M 56.82%
2023 $1.47M -79.44%
2022 $7.13M 50.00%
2021 $4.75M 4.97%
2020 $4.53M -23.61%
2019 $5.93M 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
2016 0.00 0.00%
유사 기업 또는 경쟁사의 매출
회사 매출 매출 차이 국가
$12.62B 549,098.33%
US
$6.02B 261,845.69%
NL
- -
CH
- -
KR
$10.11B 439,752.28%
BE